Cost-effectiveness of preimplantation genetic testing for aneuploidies
The use of preimplantation genetic testing for aneuploidies is highly debated. This theoretical study suggests that the procedure can be economically advantageous when used in specific settings and patient groups.
Volume 111, Issue 6, Pages 1169–1176
Edgardo Somigliana, M.D., Ph.D., Andrea Busnelli, M.D., Alessio Paffoni, M.Sc., Ph.D., Paola Vigano, M.Sc., Ph.D., Alessandra Riccaboni, M.D., Carmen Rubio, M.Sc., Antonio Capalbo, M.Sc.
To evaluate the economical benefit of preimplantation genetic testing of aneuploidies (PGT-A) when applied in an extended culture and stringent elective single ET framework.
Theoretical cost-effectiveness study.
Comparison of the cost-effectiveness between two IVF treatment strategies: serial transfer of all available blastocysts without genetic testing (first fresh transfer and subsequent frozen-thawed transfer); and systematic use of genetic testing (trophectoderm biopsy, freeze-all, and frozen-thawed transfers of euploid blastocysts). The costs considered for this analysis are based on regional public health system provider.
Main Outcome Measure(s)
Costs per live birth.
Cost-effectiveness profile of PGT-A improves with female age and number of available blastocysts. Sensitivity analyses varying the costs of ET, the costs of genetic analyses, the magnitude of the detrimental impact of PGT-A on live birth rate, and the crude live birth rates change to some extent the thresholds for effectiveness but generally confirm the notion that PGT-A can be economically advantageous in some specific subgroups.
PGT-A can be cost-effective in specific clinical settings and population groups. Economic considerations deserve attention in the debate regarding the clinical utility of PGT-A.